Dr. Christopher D Fletcher, MD
Claim this profileUniversity of Wisconsin Carbone Cancer Center
Studies Lymphoma
Studies Diffuse Large B-Cell Lymphoma
4 reported clinical trials
13 drugs studied
Area of expertise
1Lymphoma
CD20 positive
Stage II
Stage III
2Diffuse Large B-Cell Lymphoma
CD20 positive
Stage II
Stage III
Affiliated Hospitals
Clinical Trials Christopher D Fletcher, MD is currently running
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
Split-Dose R-CHOP
for Lymphoma
This study is investigating a new administration schedule of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) chemotherapy for participants with Diffuse Large B-Cell Lymphoma (DLBCL), focusing on an underserved elderly population (aged 75 and up; certain participants 70-74 may be eligible) that is often excluded from clinical trials. Participants can expect to be on study for 2.5 years (treatment for 6 months and 2 years of post treatment follow-up).
Recruiting1 award Phase 215 criteria
More about Christopher D Fletcher, MD
Clinical Trial Related5 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Christopher D Fletcher, MD has experience with
- Lenalidomide
- Rituximab
- Vincristine
- Prednisone
- Cyclophosphamide
- Doxorubicin
Breakdown of trials Christopher D Fletcher, MD has run
Lymphoma
Diffuse Large B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Christopher D Fletcher, MD specialize in?
Christopher D Fletcher, MD focuses on Lymphoma and Diffuse Large B-Cell Lymphoma. In particular, much of their work with Lymphoma has involved CD20 positive patients, or patients who are Stage II.
Is Christopher D Fletcher, MD currently recruiting for clinical trials?
Yes, Christopher D Fletcher, MD is currently recruiting for 2 clinical trials in Madison Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Christopher D Fletcher, MD has studied deeply?
Yes, Christopher D Fletcher, MD has studied treatments such as Lenalidomide, Rituximab, Vincristine.
What is the best way to schedule an appointment with Christopher D Fletcher, MD?
Apply for one of the trials that Christopher D Fletcher, MD is conducting.
What is the office address of Christopher D Fletcher, MD?
The office of Christopher D Fletcher, MD is located at: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin 53705 United States. This is the address for their practice at the University of Wisconsin Carbone Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.